Start by introducing Austedo as a brand-name drug and discuss the price premium question compared to generics. Then explain Teva’s negotiations with CMS, what they’re considering, and how this might affect the generic community or patient access.
That should cover all necessary points without getting too wordy.
**Title:** Teva Discusses Price Justification for Austedo Amid Generic Concerns
**
Source: https://insights.citeline.com/pink-sheet/market-access/government-payers/medicare/medicare-2027-negotiating-class-austedo-linzess-xifaxan-may-face-generic-otc-price-comparators-YFMV4FNYSZFNJE6LNHC2HVQCMI